Use of a blood‐based amyloid test for screening in INVOKE‐2: a phase 2 randomized, double‐blind, placebo‐controlled study evaluating AL002 in early Alzheimer’s disease
Brady Burgess, Tuan Nguyen, Adam Simmons, Ruchi Gupta, Tiffany Chow, Gary Romano · 2025
Read Use of a blood‐based amyloid test for screening in INVOKE‐2: a phase 2 randomized, double‐blind, placebo‐controlled study evaluating AL002 in early Alzheimer’s disease by Brady Burgess, Tuan Nguyen, Adam Simmons, Ruchi Gupta, Tiffany Chow, Gary Romano (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713817.txt.
Description
Brady Burgess and co-authors report in 2025 how a blood test sped screening for an Alzheimer drug trial. The trial, INVOKE-2, tested an antibody drug in early Alzheimer disease. Entry required proof of amyloid in the brain, a step that scans or spinal taps confirm at high cost.
A blood test that scores amyloid odds was used first, to weed out likely negatives. Just over half of screened people tested positive on blood. Of those, a high share went on to confirm as truly positive, with the highest scores the most reliable. The team shows that a blood-first path cuts wasted scans. The trial could thus fill its slots faster while still requiring scan or spinal proof before entry.
Catalog record
| CREATOR | Brady Burgess, Tuan Nguyen, Adam Simmons, Ruchi Gupta, Tiffany Chow, Gary Romano |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |